Commercialization Strategy
Commercialization Pathway Selector
License it, spin it out, partner, or sell it yourself? This guide explains each route and the factors that decide between them. When you want a recommendation for your own technology, the free AI GTM Strategy Generator writes one, with its reasoning.
Why the pathway decision matters
The pathway decides who carries the risk, who needs to raise money, who controls the product and how any revenue is shared. It also shapes everything that follows: a licensing route means building a case for licensees, a spin-out means building a team and a pitch for investors, and a partnership means negotiating development and IP terms before anything is sold.
The choice is hard to reverse cheaply. An exclusive license can lock up a field of use for years, and a spin-out that cannot raise its next round may leave the IP stranded. Spending a few weeks on the decision, with the factors below written down, is time well spent.
The main commercialization pathways
What each route involves, when it tends to fit, and what you give up.
Technology licensing
An established company pays for the right to use your IP, usually through an upfront fee, milestone payments and royalties on sales.
Tends to suit: Strong patents, a market dominated by incumbents with distribution, and an inventor team that does not want to run a company.
Trade-offs: Less capital and risk for you, but little control over how, or whether, the licensee brings the product to market.
Spin-out or startup
A new company is formed to develop the technology, typically licensing the IP from the university or parent company in exchange for equity and royalties.
Tends to suit: A technology that can become a product (not just a feature of someone else's), a committed founding team, and a credible path to outside funding.
Trade-offs: The most control and upside, and the most capital, time and execution risk.
Strategic partnership
You co-develop with an industry partner who brings manufacturing, regulatory experience, channels or funding, often under a joint development agreement.
Tends to suit: Technologies that need a partner's assets to reach customers, or where the partner's validation is what buyers will trust.
Trade-offs: Shared cost and faster access to market, but shared control and IP terms that need careful negotiation.
Direct sales
An existing company or lab sells the product or service itself, without a new entity or a licensee in between.
Tends to suit: Organisations that already have customers, a sales channel and the ability to support what they sell.
Trade-offs: Keeps the margin in-house, but stretches teams that were built for research rather than selling.
Outright sale or assignment
The IP is sold to a buyer for a one-time payment and all rights transfer.
Tends to suit: Non-core IP, or cases where the owner wants a clean exit and no ongoing obligations.
Trade-offs: Certain money now in exchange for giving up any future upside.
Hybrid approaches
Different routes for different fields of use, for example licensing a medical application while a spin-out pursues an industrial one.
Tends to suit: Platform technologies with several unrelated applications.
Trade-offs: Captures more of the value but needs careful field-of-use definitions and more deals to manage.
Six factors that decide the pathway
No formula picks the route for you, but the same questions come up in almost every commercialization decision. Answer each one in writing before you talk to licensees or investors.
Technology readiness
Early-stage technology (roughly TRL 1 to 3) is hard to license for meaningful terms because the licensee carries most of the development risk. It often needs grant funding or a partner to move up the scale first. By TRL 6 and beyond, with a prototype validated in a relevant environment, all routes are open. The free TRL assessment helps you place yourself honestly.
Strength and scope of the IP
Licensing depends on IP a licensee would otherwise infringe or cannot easily design around. If protection is narrow, or the value lies in know-how and the team, a spin-out or partnership that keeps the people involved is usually more realistic.
Market structure
Where a few large companies control distribution, regulatory relationships or manufacturing, licensing or partnering with one of them is often faster than competing. Fragmented markets with many reachable buyers are friendlier to a startup.
Capital required to reach revenue
Count everything between today and the first paying customer: development, manufacturing scale-up, certification, clinical or field trials. The larger that number, the more you need either investors (spin-out) or a partner that already has the capability.
The people
A spin-out needs someone willing to run it full time. Many successful inventors prefer to stay in research. That is a legitimate reason to choose licensing, and it is better to say so early than to start a company nobody wants to lead.
Institutional rules
Universities and corporate labs have policies on equity, conflicts of interest, revenue sharing and who may negotiate. The tech transfer office will know them, and they shape what is possible before any market question is asked.
How the free strategy report helps
The AI GTM Strategy Generator is the part of Commercify that does this today. Here is exactly what it does:
- You describe the technology, choose an industry and development stage (from concept at TRL 1 to 3 through market-ready at TRL 9), name a target customer, and pick a goal: licensing, spin-out, partnership, direct sales, or "not sure, recommend one".
- After you confirm your email, Claude writes a report with an executive summary, market assessment, recommended pathway, target segments, pricing strategy, launch plan, risks, validation experiments, funding and resources, and next steps.
- From the report you can run optional deep dives: pressure-testing the pricing, turning the first validation experiment into a step-by-step protocol, or drafting first-contact outreach emails matched to your pathway.
What it does not do: it does not read your patents, check your institution's policies, or score every pathway against the others. It gives one recommendation and its reasoning, which is a useful starting point for a conversation with your tech transfer office or advisers.
Other free tools for this decision
- TRL assessment: one question per level to estimate your readiness from 1 to 9, with next steps and funding fit.
- Patent and IP planner: filing timelines and licensing frameworks to think through your IP position.
- Find licensing opportunities: describe a company focus and find universities with matching technologies available to license.
- SBIR/STTR navigator: find federal agencies and check eligibility for non-dilutive funding that can move early technology up the TRL scale.
- University tech transfer directory: US university tech transfer offices with sourced metrics.
Frequently Asked Questions
Is there a standalone pathway selector tool?
Not as a separate product. The pathway recommendation lives inside the free AI GTM Strategy Generator. You describe your technology, industry, development stage and goal (or choose 'not sure'), and the report includes a recommended pathway with its reasoning, along with market, pricing, launch, risk and validation sections.
Does the report rank every pathway?
No. It recommends one primary pathway and explains why, based on what you entered. It does not score all six options. If you want to compare two routes, run the generator twice with different goals selected and read the reasoning side by side.
How accurate is the recommendation?
It is a structured first opinion written by Claude, a large language model, from your description. It has no access to your patents, your institution's policies or live market data, so it can be wrong. Use it to frame the discussion with your tech transfer office, advisers or potential partners, not to replace it.
When is licensing a better choice than a spin-out?
Licensing tends to fit when the IP is strong, incumbents already control the route to customers, the capital needed to reach revenue is large, and the inventors want to stay in research. A spin-out fits when the technology can stand alone as a product and there is a team ready to build a company around it.
Can I change pathways later?
Often, yes. Many technologies start with grant-funded development, move to a partnership for validation, and only then license or spin out. The main constraint is that an exclusive license or an assignment can close off other routes, so check field-of-use and exclusivity terms carefully before signing.
Get a first recommendation for your technology
The report is free and takes a few minutes to request. Read the reasoning, then test it against the six factors above.